Tourmaline Bio, Inc. (TRML) Stock Overview
Explore Tourmaline Bio, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Tourmaline Bio, Inc. (TRML)
Key Financials
Key Financials
Market Cap
1.2B
P/E Ratio
-26.80
EPS (TTM)
$-3.44
ROE
-0.17%
TRML Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Tourmaline Bio, Inc. (NASDAQ: TRML) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Tourmaline Bio, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of TRML on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $35.04 for the NASDAQ listing.
Key metrics behind Tourmaline Bio, Inc.'s NASDAQ-traded stock include a P/E ratio of -26.80 and a market capitalization of 1.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of TRML on the NASDAQ.